Effectiveness of Oral Hyaluronic Acid in Knee Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was a randomized, double-blind, placebo-controlled study evaluating the efficacy of an oral liquid HA supplement (A+HA) in symptoms relief and improvement of quality of life in knee osteoarthritis patients with mild knee pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of Oral Hyaluronic Acid (A+ HA(tm), TOP Pharm.) in Knee Osteoarthritis: Clinical Trial

NCT04212741

Knee Osteoarthritis

COMPLETED NA

Therapeutic Effect of Oral Hyaluronic Acid on Knee Osteoarthritis

NCT07033312

Knee Osteoarthritis

RECRUITING NA

The Effect of Oral Hyaluronic Acid (UltraHA®) on the Knee Function

NCT05683327

Healthy Japanese Subjects

COMPLETED NA

Effects of Knee Injections on Patients With Knee Osteoarthritis

NCT05220527

Knee Osteoarthritis Injection Effect of Drug

UNKNOWN PHASE4

The Long-term Evaluation of Glucosamine Sulphate Study

NCT00513422

Osteoarthritis, Knee

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects were initially screened at the Randomization/Baseline Visit (Week 0). Eligible subjects were randomized at the same visit into the treatment period and received the assigned treatment in a double-blind fashion for 8 weeks. During the 8 weeks treatment period, there were three follow-up visits requested (Week 2, Week 4 and Week 8). Efficacy was measured by using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the Short Form-36 (SF-36).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A+HA(tm)

20 ml oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin in a bottle. Administration with 250\~500 ml water under fasting condition in the morning.

Group Type EXPERIMENTAL

A+HA(tm)

Intervention Type DIETARY_SUPPLEMENT

oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin

Placebo

20 ml oral solution without active ingredients in a bottle. Administration with 250\~500 ml water under fasting condition in the morning.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

oral solution with no active ingredients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

A+HA(tm)

oral solution of hyaluronic acid mixture in combination with glucosamine and chondroitin

Intervention Type DIETARY_SUPPLEMENT

Placebo

oral solution with no active ingredients

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female age \>= 40 years old
* Diagnosed with knee OA which met the definition of Ahlbӓck classification12 and had knee joint symptoms within 30 days prior to enrollment

Exclusion Criteria

* Had administered glucosamine one month prior to enrollment
* Had known allergy to oral HA
* BMI ≧40 kg/m2
* Knee OA was caused by occupational hazard or sports injury
* Patients with known other causes of arthritis (infectious rheumatoid or psoriatic arthritis), bony or soft tissue malignancy or peripheral neuropathy involving the lower extremities, cardiopulmonary disease which limited walking more than knee pain, knee instability defined as a report of knee buckling or locking within the past month of the study knee, major neurological deficit that affected gait, psychiatric illness that limited informed consent or Parkinsonism
* Women in pregnancy
* Wheel chair users

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No